C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Additional Data Presented Demonstrate High In Vitro Antiviral Potency and In Vivo Efficacy for AT-587, Atea’s Potential First-in-Class Direct-Acting Antiviral for the Treatment of Hepatitis E ...

Trial design can optimize a drug's chances for success. Patient-centered outcomes are the best endpoints for trials. In order to begin, one must compare the Merck and Atea trials. Both examined ...

Atea Pharmaceuticals (NASDAQ:AVIR) said it remains on track for two key Phase 3 hepatitis C readouts in 2026 while advancing ...

Shares of the mid-cap biopharma Atea Pharmaceutical (NASDAQ: AVIR) are up by a respectable 21.5% as of 11:44 a.m. EDT Friday morning. The biotech's shares are taking flight today in response to a ...

Atea Pharmaceuticals (AVIR) announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as ...

Atea ASA ( (ATAZF)) just unveiled an update. Atea ASA has continued to execute on its previously announced share buyback program, repurchasing 35,000 shares on the Oslo Stock Exchange between 19 March ...

Shares of Atea Pharmaceuticals (AVIR 1.60%) fell by as much as 14.4% in premarket trading Wednesday morning. The biotech's shares are sliding today in response to Roche's (RHHBY +1.29%) decision to ...